A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy
The article discusses the common pathogenetic pathways of autoimmune skin diseases – psoriasis and vitiligo. Currently proposed treatments for vitiligo do not significantly reduce or completely restore skin pigmentation. The use of adalimumab for 6 years in a patient suffering from psoriasis, psoria...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1237 |
_version_ | 1826556836276338688 |
---|---|
author | N. S. Rudneva E. V. Natarova V. N. Sorotskaya T. G. Sadunashvili |
author_facet | N. S. Rudneva E. V. Natarova V. N. Sorotskaya T. G. Sadunashvili |
author_sort | N. S. Rudneva |
collection | DOAJ |
description | The article discusses the common pathogenetic pathways of autoimmune skin diseases – psoriasis and vitiligo. Currently proposed treatments for vitiligo do not significantly reduce or completely restore skin pigmentation. The use of adalimumab for 6 years in a patient suffering from psoriasis, psoriatic arthritis (PsA), vitiligo and autoimmune thyroiditis made it possible to control the activity of psoriasis and PsA, and also contributed to the regression of depigmentation foci. The use of biologic disease-modifying antirheumatic drug therapy in this group of patients in order to achieve repigmentation may be promising. |
first_indexed | 2024-04-10T02:05:18Z |
format | Article |
id | doaj.art-57cd13e9122144b1af2ad2779f82964f |
institution | Directory Open Access Journal |
issn | 1996-7012 2310-158X |
language | Russian |
last_indexed | 2025-03-14T08:19:02Z |
publishDate | 2021-12-01 |
publisher | IMA-PRESS LLC |
record_format | Article |
series | Современная ревматология |
spelling | doaj.art-57cd13e9122144b1af2ad2779f82964f2025-03-02T13:11:06ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2021-12-0115610611010.14412/1996-7012-2021-6-106-1102434A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapyN. S. Rudneva0E. V. Natarova1V. N. Sorotskaya2T. G. Sadunashvili3Tula Regional Clinical Skin and Venereal Diseases DispensaryTula Regional Clinical Skin and Venereal Diseases DispensaryTula Regional Clinical Skin and Venereal Diseases DispensaryTula Regional Clinical Skin and Venereal Diseases DispensaryThe article discusses the common pathogenetic pathways of autoimmune skin diseases – psoriasis and vitiligo. Currently proposed treatments for vitiligo do not significantly reduce or completely restore skin pigmentation. The use of adalimumab for 6 years in a patient suffering from psoriasis, psoriatic arthritis (PsA), vitiligo and autoimmune thyroiditis made it possible to control the activity of psoriasis and PsA, and also contributed to the regression of depigmentation foci. The use of biologic disease-modifying antirheumatic drug therapy in this group of patients in order to achieve repigmentation may be promising.https://mrj.ima-press.net/mrj/article/view/1237psoriasispsoriatic arthritisgeneralized vitiligoadalimumabtumor necrosis factor α inhibitorautoimmune diseases. |
spellingShingle | N. S. Rudneva E. V. Natarova V. N. Sorotskaya T. G. Sadunashvili A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy Современная ревматология psoriasis psoriatic arthritis generalized vitiligo adalimumab tumor necrosis factor α inhibitor autoimmune diseases. |
title | A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy |
title_full | A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy |
title_fullStr | A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy |
title_full_unstemmed | A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy |
title_short | A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy |
title_sort | case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy |
topic | psoriasis psoriatic arthritis generalized vitiligo adalimumab tumor necrosis factor α inhibitor autoimmune diseases. |
url | https://mrj.ima-press.net/mrj/article/view/1237 |
work_keys_str_mv | AT nsrudneva acaseofvitiligoregressioninapatientwithpsoriasisandpsoriaticarthritisreceivingadalimumabtherapy AT evnatarova acaseofvitiligoregressioninapatientwithpsoriasisandpsoriaticarthritisreceivingadalimumabtherapy AT vnsorotskaya acaseofvitiligoregressioninapatientwithpsoriasisandpsoriaticarthritisreceivingadalimumabtherapy AT tgsadunashvili acaseofvitiligoregressioninapatientwithpsoriasisandpsoriaticarthritisreceivingadalimumabtherapy AT nsrudneva caseofvitiligoregressioninapatientwithpsoriasisandpsoriaticarthritisreceivingadalimumabtherapy AT evnatarova caseofvitiligoregressioninapatientwithpsoriasisandpsoriaticarthritisreceivingadalimumabtherapy AT vnsorotskaya caseofvitiligoregressioninapatientwithpsoriasisandpsoriaticarthritisreceivingadalimumabtherapy AT tgsadunashvili caseofvitiligoregressioninapatientwithpsoriasisandpsoriaticarthritisreceivingadalimumabtherapy |